Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

CureVac NV

CVAC
Current price
3.54 USD -0.11 USD (-3.01%)
Last closed 3.77 USD
ISIN NL0015436031
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 695 447 808 USD
Yield for 12 month +4.42 %
1Y
3Y
5Y
10Y
15Y
CVAC
21.11.2021 - 28.11.2021

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. Address: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.25 USD

P/E ratio

6.46

Dividend Yield

Current Year

+56 472 165 USD

Last Year

+70 823 940 USD

Current Quarter

+518 838 412 USD

Last Quarter

+15 164 853 USD

Current Year

-74 172 898 USD

Last Year

-122 458 605 USD

Current Quarter

+495 800 147 USD

Last Quarter

-27 614 193 USD

Key Figures CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -270 342 016 USD
Operating Margin TTM -493.58 %
PE Ratio 6.46
Return On Assets TTM -24.52 %
PEG Ratio
Return On Equity TTM -54.30 %
Wall Street Target Price 7.25 USD
Revenue TTM 65 859 000 USD
Book Value 1.68 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 90.50 %
Dividend Yield
Gross Profit TTM -91 549 000 USD
Earnings per share 0.48 USD
Diluted Eps TTM 0.48 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CVAC

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CVAC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 6.46
Forward PE 5.24
Enterprise Value Revenue 0.27
Price Sales TTM 10.56
Enterprise Value EBITDA 0.89
Price Book MRQ 0.91

Financials CVAC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CVAC

For 52 weeks

2.22 USD 5.28 USD
50 Day MA 2.84 USD
Shares Short Prior Month 4 410 820
200 Day MA 3.16 USD
Short Ratio 7.37
Shares Short 4 210 816
Short Percent 10.50 %